Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060043 | 0.91 | RIPK1 (0.52) | RIPK1GRM5MCHR1KITSMYD3 | |
| SCHEMBL2060124 | 0.86 | RIPK1 (0.47) | RIPK1MAPK14MAPK11GRM5MCHR1 | |
| SCHEMBL2060253 | 0.85 | RIPK1 (0.48) | RIPK1MAPK14MAPK11GRM5MCHR1 | |
| SCHEMBL885793 | 0.84 | RIPK1 (0.42) | RIPK1GRM5MCHR1GABRA5 | |
| SCHEMBL885847 | 0.82 | RIPK1 (0.48) | RIPK1GRM5MCHR1KITSMYD3 | |
| SCHEMBL885593 | 0.82 | MCHR1 (0.45) | RIPK1MAPK14MAPK11GRM5MCHR1 | |
| SCHEMBL885585 | 0.79 | RIPK1 (0.45) | RIPK1MCHR1KITRIPK2ADRA2A | |
| SCHEMBL885701 | 0.79 | RIPK1 (0.52) | RIPK1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL885846 | 0.75 | KDR (0.41) | RIPK1MAPK14MAPK11GRM5MCHR1 | |
| SCHEMBL2060016 | 0.74 | GRM5 (0.41) | MAPK14GRM5MCHR1KITRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | claimed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | claimed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | claimed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | claimed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | claimed |
| EP-2081928-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | claimed |
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | RIPK1 850/4885MAPK14 229/4885MAPK13 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.